![grand rounds_jfma_sept 2010[1]](http://s1.studyres.com/store/data/008716063_1-ee5a6ebf54ee055e171e483da7bf202c-300x300.png)
grand rounds_jfma_sept 2010[1]
... mg daily; if glycemic response is not optimal, may increase to 1.8 mg daily ...
... mg daily; if glycemic response is not optimal, may increase to 1.8 mg daily ...
MYCOPHENOLATE MOFETIL for Connective Tissue Disease
... monthly blood monitoring should be made clear to the patient/carer. The advice to the patient/carer should cover: a. The potential side effects and the action to be taken should they occur (particularly in relation to reporting any infection, unexplained bruising/bleeding or persistent cough or brea ...
... monthly blood monitoring should be made clear to the patient/carer. The advice to the patient/carer should cover: a. The potential side effects and the action to be taken should they occur (particularly in relation to reporting any infection, unexplained bruising/bleeding or persistent cough or brea ...
Exam One Notes
... Drugs Used Against Malaria - Malaria is a vicious disease which accounts for annual 1.5 – 2.5 million deaths, worldwide, mostly children < 5 yo. - ~40% of the world population live in areas with the risk of malaria - About 273 million malaria cases were reported in 1998 and the worldwide average ann ...
... Drugs Used Against Malaria - Malaria is a vicious disease which accounts for annual 1.5 – 2.5 million deaths, worldwide, mostly children < 5 yo. - ~40% of the world population live in areas with the risk of malaria - About 273 million malaria cases were reported in 1998 and the worldwide average ann ...
file (Parkinsons Disease Topic
... manifestation of Parkinson’s Disease (PD) Determine appropriate first-line therapy for Parkinson’s Disease Determine appropriate adjunct therapeutic agents for Parkinson’s Disease List treatment complications and understand how to augment therapy accordingly ...
... manifestation of Parkinson’s Disease (PD) Determine appropriate first-line therapy for Parkinson’s Disease Determine appropriate adjunct therapeutic agents for Parkinson’s Disease List treatment complications and understand how to augment therapy accordingly ...
THE FIRST-AND-ONLY ONE DOSE IV treatment for flu
... Influenza can be associated with a variety of neurologic and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur in uncomp ...
... Influenza can be associated with a variety of neurologic and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur in uncomp ...
fast dissolving tablets: preparation, characterization and evaluation
... simvastatin applied for in Japan in 2004. Marketers build a better brand and in this way company’s reputation can be improved. CHARACTERISTICS: FDDTs, as a novel dosage form, have several characteristics to distinguish them from the more traditional dosage forms. Traditional tablet formulations gene ...
... simvastatin applied for in Japan in 2004. Marketers build a better brand and in this way company’s reputation can be improved. CHARACTERISTICS: FDDTs, as a novel dosage form, have several characteristics to distinguish them from the more traditional dosage forms. Traditional tablet formulations gene ...
Quick Notes WHAT ARE STIMULANTS?
... through the nose with a rolled-up piece of paper or currency. The high from snorting cocaine typically lasts 15 to 30 minutes. ...
... through the nose with a rolled-up piece of paper or currency. The high from snorting cocaine typically lasts 15 to 30 minutes. ...
Document
... treatment of AA with variable results ranged from no significant response to 80%. Accordingly, zinc sulphate has been used in this study as a systemic treatment for patchy AA. In the present work, the serum zinc levels were within the normal range that increased significantly after 3 months of treat ...
... treatment of AA with variable results ranged from no significant response to 80%. Accordingly, zinc sulphate has been used in this study as a systemic treatment for patchy AA. In the present work, the serum zinc levels were within the normal range that increased significantly after 3 months of treat ...
What are effective medication combinations for dyslipidemia?
... effects for combined dyslipidemia (SOR: A). Most combination therapies increase the risk of intolerance or side effects, including myopathy. The statin/gemfibrozil combination has the highest risk of myopathy, whereas statin/ ezetimibe or statin/bile acid sequestrant have the ...
... effects for combined dyslipidemia (SOR: A). Most combination therapies increase the risk of intolerance or side effects, including myopathy. The statin/gemfibrozil combination has the highest risk of myopathy, whereas statin/ ezetimibe or statin/bile acid sequestrant have the ...
Hospital brochure - LMA™ Better by design
... The unique design of LMA MAD Nasal™ enables a seal to be formed with the nostril and atomized particles of medication to be delivered to the nasal mucosa. The particles are then absorbed through the mucosal tissue and into the bloodstream, avoiding first pass metabolism. ...
... The unique design of LMA MAD Nasal™ enables a seal to be formed with the nostril and atomized particles of medication to be delivered to the nasal mucosa. The particles are then absorbed through the mucosal tissue and into the bloodstream, avoiding first pass metabolism. ...
The Effects of Betahistine and Dimenhydrinate on Caloric Test
... caloric test may be misleading, but the statistical analysis demonstrated that these findings are statistically important. Though SPV may change in different caloric test sessions in the same patient on repetitive examinations, statistical analysis shows that our findings are not coincidental. Some ...
... caloric test may be misleading, but the statistical analysis demonstrated that these findings are statistically important. Though SPV may change in different caloric test sessions in the same patient on repetitive examinations, statistical analysis shows that our findings are not coincidental. Some ...
NSAIDs: Friend or Foe
... may be used in those with a history of ulceration Always consider prescribing gastric protection in form of PPI for those requiring long-term tNSAIDs OR coxibs NICE judged that it is cost-effective to add generic PPI to tNSAIDs or coxibs used as treatment for rheumatoid or osteoarthritis NICE advise ...
... may be used in those with a history of ulceration Always consider prescribing gastric protection in form of PPI for those requiring long-term tNSAIDs OR coxibs NICE judged that it is cost-effective to add generic PPI to tNSAIDs or coxibs used as treatment for rheumatoid or osteoarthritis NICE advise ...
14 Medicines management Janet Krska and Brian Godman Sample chapter copyright Pharmaceutical Press
... improving health outcomes, including minimising adverse drug reactions and drug–drug interactions. All require interventions designed to influence behaviour, in both health professionals and patients. The main strategies currently used to achieve this can be described as the ‘four Es’: education, en ...
... improving health outcomes, including minimising adverse drug reactions and drug–drug interactions. All require interventions designed to influence behaviour, in both health professionals and patients. The main strategies currently used to achieve this can be described as the ‘four Es’: education, en ...
Pharmacology
... • In order to receive permission from the FDA to administer the drug to humans in a clinical trial and garner data for safety and efficacy, the drug company must have pre-clinical data. • The drug will be given to animals • There is an understanding that it is meant for eventual use in humans ...
... • In order to receive permission from the FDA to administer the drug to humans in a clinical trial and garner data for safety and efficacy, the drug company must have pre-clinical data. • The drug will be given to animals • There is an understanding that it is meant for eventual use in humans ...
Viekira Pak™ Prior Authorization Worksheet for Prescribers
... Hepatic decompensation and hepatic failure, including liver transplantation or fatal outcomes have been identified in postmarketing surveillance reports. For patients with cirrhosis it is recommended to monitor for clinical signs and symptoms of hepatic decompensation and conduct hepatic laboratory ...
... Hepatic decompensation and hepatic failure, including liver transplantation or fatal outcomes have been identified in postmarketing surveillance reports. For patients with cirrhosis it is recommended to monitor for clinical signs and symptoms of hepatic decompensation and conduct hepatic laboratory ...
PULMONARY TUBERCULOSIS
... dorsal segments of the lower lobes and posterior segments of the upper lobes. Typically lung abscess causes litt1e in the way of physical findings, may have a fluid level, and is not associated with patchy bronchogenic infiltrates. In contrast, physical findings are prominent over tuberculous caviti ...
... dorsal segments of the lower lobes and posterior segments of the upper lobes. Typically lung abscess causes litt1e in the way of physical findings, may have a fluid level, and is not associated with patchy bronchogenic infiltrates. In contrast, physical findings are prominent over tuberculous caviti ...
NSAIDs: Friend or Foe
... may be used in those with a history of ulceration Always consider prescribing gastric protection in form of PPI for those requiring long-term tNSAIDs OR coxibs NICE judged that it is cost-effective to add generic PPI to tNSAIDs or coxibs used as treatment for rheumatoid or osteoarthritis NICE advise ...
... may be used in those with a history of ulceration Always consider prescribing gastric protection in form of PPI for those requiring long-term tNSAIDs OR coxibs NICE judged that it is cost-effective to add generic PPI to tNSAIDs or coxibs used as treatment for rheumatoid or osteoarthritis NICE advise ...
PSL2023 Pharma-Search Ltd Prepared by: Dr Grant R. Coren
... In June 2006, the FDA approved REVLIMID in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. REVLIMID is only available through a restricted distribution program called RevAssist®. EMEA approval for the REVLIMID® multiple myel ...
... In June 2006, the FDA approved REVLIMID in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. REVLIMID is only available through a restricted distribution program called RevAssist®. EMEA approval for the REVLIMID® multiple myel ...
Urine Opiate Tests for Pain Management 2/15/2014
... immunoassays run in CLIA-certified laboratories. Alternatively, new targeted laboratorydeveloped screening assays using mass spectrometry have also started to emerge as a screening tool. Each of these types of assays has advantages and disadvantages. Point-of-care tests have the advantage of having ...
... immunoassays run in CLIA-certified laboratories. Alternatively, new targeted laboratorydeveloped screening assays using mass spectrometry have also started to emerge as a screening tool. Each of these types of assays has advantages and disadvantages. Point-of-care tests have the advantage of having ...
Letairis
... patient experienced a mild aminotransferase elevation at 12 weeks on Letairis 5 mg that resolved with decreasing the dosage to 2.5 mg, and that did not recur with later escalations to 10 mg. With a median follow-up of 13 months and with 50% of patients increasing the dose of Letairis to 10 mg, no pa ...
... patient experienced a mild aminotransferase elevation at 12 weeks on Letairis 5 mg that resolved with decreasing the dosage to 2.5 mg, and that did not recur with later escalations to 10 mg. With a median follow-up of 13 months and with 50% of patients increasing the dose of Letairis to 10 mg, no pa ...
Exceptional Cases and Individual Funding Requests
... The patient or their clinical condition is shown to be significantly different when compared with a similar group of patients who are suffering from the same condition. Exceptional clinical circumstances refers to a patient who has clinical circumstances which, taken as a whole, are outside the rang ...
... The patient or their clinical condition is shown to be significantly different when compared with a similar group of patients who are suffering from the same condition. Exceptional clinical circumstances refers to a patient who has clinical circumstances which, taken as a whole, are outside the rang ...
Clinical_PA_ST_Updates_Jan2011
... therapy. Patient must be 18 years or older and have a diagnosis of constipation predominant Irritable Bowel Syndrome (female only) OR chronic idiopathic constipation with documented failure with one fiber laxative and either a stimulant or osmotic laxative within the last 12 months. Drug induced con ...
... therapy. Patient must be 18 years or older and have a diagnosis of constipation predominant Irritable Bowel Syndrome (female only) OR chronic idiopathic constipation with documented failure with one fiber laxative and either a stimulant or osmotic laxative within the last 12 months. Drug induced con ...
ISMP Medication Safety Alert - Institute For Safe Medication Practices
... site. To promote such a process, the following selected agenda items have been prepared for your senior leaders and an interdisciplinary committee to stimulate discussion and action to reduce the risk of medication errors. These agenda items appeared in the ISMP Medication Safety Alert! between Apri ...
... site. To promote such a process, the following selected agenda items have been prepared for your senior leaders and an interdisciplinary committee to stimulate discussion and action to reduce the risk of medication errors. These agenda items appeared in the ISMP Medication Safety Alert! between Apri ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.